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Background: The objective of the study was to analyse whether azacitidine is a cost-effective option for the
treatment of myelodysplastic syndrome in the Spanish setting compared with conventional care regimens,
including best supportive care, low dose chemotherapy and standard dose chemotherapy.
Methods: A life-time Markov model was constructed to evaluate the cost-effectiveness of azacitidine compared
with conventional care regimens. The health states modelled were: myelodysplastic syndrome, acute myeloid
leukemia and death. Variables measured included survival rates, progression probabilities and quality of life
indicators. Resource use and cost data reflect the Spanish context. The analysis was performed from the Spanish
National Health System perspective, discounting both costs (in 2012 euros) and future effects at 3%. The time
horizon considered was end-of-life. Results were expressed in cost per quality-adjusted life-year gained and cost per
life-year gained and compared with cost-effectiveness thresholds.
Results: According to the current use of each conventional care regimens options in Spain, azacitidine resulted in
€34,673 per quality-adjusted life-year gained (€28,891 per life-year gained) with an increase of 1.89 in quality-
adjusted life-years (2.26 in life-years). Azacitidine was superior to best supportive care and low dose chemotherapy
in terms of quality-adjusted life-years gained, 1.82 and 2.03, respectively (life-years 2.16 vs. best supportive care, 2.39
vs. low dose chemotherapy). Treatment with azacitidine resulted in longer survival time and thus longer treatment
time and lifetime costs. The incremental cost-effectiveness ratio was €39,610 per quality-adjusted life-year gained vs.
best supportive care and €30,531 per quality-adjusted life-year gained vs. low dose chemotherapy (€33,111 per
life-year gained vs. best supportive care and €25,953 per life-year gained vs. low dose chemotherapy).
Conclusions: The analysis showed that the use of azacitidine in the treatment of high-risk myelodysplastic syndrome
is a cost-effective option compared with conventional care regimen options used in the Spanish setting and had an
incremental cost-effectiveness ratio within the range of the thresholds accepted by health authorities.
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Myelodysplastic syndrome (MDS) is a group of medical
conditions derived from progressive bone marrow failure
that result in ineffective production of blood cells. De-
pending on the severity, MDS reduces the quality of life to
the point of being life-threatening. There is a probability* Correspondence: carlos.crespo@oblikue.com
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2013of death at all stages of the disease, due to complications
and co-morbidities, with progression to acute myeloid leu-
kaemia (AML) being the worst evolution [1]. Together
with advanced age, exposure to tobacco and some chem-
ical agents and previous chemotherapy as treatment for
non-related diseases are potential risk factors [1]. The
International Prognostic Scoring System (IPSS) identified
three critical factors that influence survival and AML evo-
lution: risk-based cytogenetic subgroups (good, intermedi-
ate and poor karyotypes), bone marrow blast percentage
and the number of cytopenias. According to these factors,an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Markov model structure. MDS =myelodysplastic
syndrome; AML = acute myeloid leukaemia.
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low and intermediate-1 groups are described as lower-risk
patients associated with longer median survival and time
to progression to AML; the intermediate-2 and high
groups, in contrast, are associated with poor median sur-
vival and shorter median time to progression to AML [2].
MDS patients have a 20-30% probability of progression
to AML and a 40-65% probability of death due to compli-
cations and co-morbidities, with the frequency depending
on age and comorbidities [1]. Therefore, a careful differen-
tial diagnosis is required for rapid identification and treat-
ment of the disease.
The conventional care regimen (CCR) for high-risk MDS
is best supportive care (BSC), low-dose chemotherapy
(LDC) or standard dose chemotherapy (SDC) [3]. Treat-
ments are associated with a survival rate of 1.2 years for
intermediate-2 stage MDS and 0.4 years for high [2]. BSC
is a common choice of treatment for high-risk MDS pa-
tients but is only palliative and no improvement in overall
survival (OS) or progression to AML has been shown com-
pared with LDC which, despite its clinical benefits is asso-
ciated with potentially high infection rates [4]. SDC is
associated with high mortality (<35%), short duration of re-
mission (usually less than 12 months), prolonged hospital-
isation and a significant reduction in quality of life [5-7].
Allogeneic stem cell transplantation is the only potentially
curative treatment available but is only feasible in 5% of pa-
tients depending on the availability of a suitable donor, age
and comorbidities [8]. Several studies have compared aza-
citidine to current treatment options and have shown large
improvements in survival and quality of life. AZA-001, an
international, multicentre, controlled, open label, rando-
mised, parallel-group, comparative phase III study showed
a significant median gain in OS of 9.4 months (12.9 vs.
BSC, 9.1 vs. LDC and 8.7 vs. SDC) [9]. The CALGB 9221,
a prospective, open label, multicentre, randomised,
controlled phase III study conducted by the Cancer and
Leukemia Group B (CALGB) confirmed a median OS
increase in survival of 8.5 months and a statistically
significant improvement in physical functioning, fatigue
and dyspnoea [10].
Spanish guidelines recommend azacitidine in the treat-
ment of patients who are not eligible for haematopoietic
stem cell transplantation with IPSS intermediate-2 and
high-risk MDS and patients with low-risk MDS after
failure of erythropoiesis-stimulating agents and patients
with chromosome 5q deletion MDS after lenalidomide
failure [11].
Positive clinical results require economic evaluation in
order to make appropriate healthcare decisions on cost
and resource use. The objective of this study was to
assess whether azacitidine is a cost-effective treatment
from the Spanish health perspective compared with
CCR options.Methods
Azacitidine was compared with CCR treatment options
using a cost-effectiveness economic analysis based on a
life-time Markov model.
The model simulated MDS management by assigning
cost and health values to the transition probabilities of three
mutually exclusive health states arising from the evolution
of MDS over a life-time period. Patients were assumed to
start in the MDS state and receive first-line treatment (aza-
citidine, BSC, LDC or SDC) and then either die or progress
to AML with consequent progression to death. Once they
progressed to AML they only received BSC. The health
states modelled were MDS with/without treatment, AML
and death. Survival rates, progression probabilities and
quality of life indicators were measured (Figure 1).
A MEDLINE literature search was carried out to ob-
tain data up to June 2012 on the efficacy of azacitidine
and comparators using the keywords: azacitidine, high-
risk myelodysplastic syndrome and phase III clinical
trial. Articles referring to comparators not indicated for
the treatment of high-risk MDS or which are not li-
censed in Spain, were excluded. The efficacy data used
in the model was taken from the AZA-001 randomized
clinical trial which included 358 high-risk MDS patients
who received azacitidine, BSC, LDC or SDC [9]. Median
OS and the median time to progress to AML were the
main efficacy results assessed in the study, while safety
results referred mainly to adverse events (AE).
To estimate survival beyond that observed in the AZA-
001 trial, the adjustment of the survival curves to different
probability distributions (Weibull, exponential, log-normal
and logistic) was analysed using statistical techniques.
The distribution selected was that which best fit the ob-
served data. Finally, the 2-year survival curves for each
treatment arm were extrapolated using the log-normal dis-
tribution. The model also considered treatment cessation
for each treatment arm, which was extrapolated in the
Table 1 Unit costs of resources
Resources Cost per unit Description
Inpatient hospital stay
(€ per days)
€742.91 standard length of stay
28 days
Haematologist €62.22 Standard MDS visit
Nurse €33.20 Average cost
Test
Biochemical Profile €44.03 Average cost
Bone Marrow (Aspirate) €133.80 Average cost





Neutropenia €68 Medical visit and analytics
Leucopenia €68 Medical visit and analytics
Febrile neutropenia €3,735 RDG 722. Simple pneumonia
and pleurisy
Pyrexia €3,735 RDG 722. Simple pneumonia
and pleurisy
Pneumonia €3,735 RDG 722. Simple pneumonia
and pleurisy
Sepsis €3.728 ICD 205.00
Abbreviations: MDS = myelodysplastic syndrome; DRG = Diagnosis-Related
Group; ICD = International Classification of Diseases.
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progression to AML. The mortality rate from AML was
assumed to be the same for all treatment arms: 0.135 per 5-
week cycle [9].
Utility scores were introduced into the model to assess pa-
tients’ preferences for the health outcomes and build the re-
sult variable, quality-adjusted life year (QALY). Utility scores
are measured on an interval scale with zero representing
health states equivalent to death and one representing
perfect health. When generic utility scores (EQ-5D) were
not available, a mapping procedure was used. MDS and
BSC utility scores were mapped to translate the European
Organization for Research and Treatment of Cancer
(EORTC QLQ-C30) scores from the CALGB study to EQ-
5D scores using regression analysis [12,13]. SF-12 utility
scores for LDC and SDC [7] were mapped to EQ-5D values
using regression analysis and Monte Carlo simulation [14].
Quality of life was similar for all treatment arms: the
baseline utility score in the MDS state was 0.67 for azaciti-
dine, BSC and LDC and 0.66 for SDC [13]. Patients with
AML had a worse quality of life than those with MDS,
which had a utility score of 0.52 [15]. As the CALGB study
only considered the quality of life of patients with MDS
up to 182 days and in the absence of long term evidence
of quality of life with MDS, it was assumed that this would
remain constant during the follow-up period.
All available health state management costs per
unit were adapted from the Spanish Cost Database [16]
(Table 1) and pharmaceutical costs were taken from a
specific local database [17] (Table 2). The model as-
sumed wastage for all pharmacological options. Costs
were expressed in 2012 euros and costs and effects were
discounted by 3% over a life-time horizon.
The burden per cycle included both MDS on and off
treatment costs and AML-related expenses. Untreated
MDS and AML reflected the cost of BSC with a different
resource use pattern, while treated MDS adds pharmaco-
logical treatment and its administration cost (Table 3).
Follow-up appointments represent routine haematologist
and nurse visits and were the same for all MDS patients re-
gardless of the type of treatment (2 haematologist and 2
nurse visits). However, patients in AML state only attended
3 haematologist visits. The typical routine tests applied for
assessing MDS disease evolution are: biochemistry profile,
full blood count and bone marrow aspiration. There are
only slight differences between the cost of routine tests in
AML and MDS off treatment state due to fewer full blood
count tests (2 vs. 1) but there are large differences in medi-
cation options, mainly due to the bone marrow aspiration
test needed for pharmacological therapy. Concurrent medi-
cation also varied depending on whether the patients were
on/off pharmacological treatment or had AML, which re-
sulted in greater costs for AML than for the other states. A
large part of the total cost was due to transfusions, whichincluded blood and platelet transfusions, and varied accord-
ing to the treatment arm depending on the number of units
administrated in the AZA-001 study (the cost for AML was
assumed to be equal to the cost for BSC) (Table 3).
In patients on treatment, AE were modelled using
AZA-001 annualized clinical trial data and the AE rate per
five-week cycle was calculated. In patients off treatment,
the annualized AE rate for BSC was used. AE costs for
each treatment arm were calculated by multiplying local
AE resource use cost data [16] by the AE rates obtained.
To obtain the necessary inputs and arrive at a consensus
on resource use, two medical specialists, one hospital
pharmacist and one haematologist participated in two
rounds of independently-answered clinical surveys. All unit
costs and results were validated by this expert group.
In terms of clinical benefits, results were expressed as
life-years (LYs) gained and QALYs gained. From the cost
perspective, the total cost of each alternative and the cost
per cycle were compared. In terms of cost-effectiveness,
the incremental cost per LY gained and QALY gained was
compared with cost-effectiveness thresholds.
Costazacitidine − CostCCR
Effectivenessazacitidine − EffectivenessCCR
A cost-effectiveness threshold is the amount of money
the decision maker is willing to pay for each LY or
Table 2 Pharmacological pattern and cost per cycle
Treatment Cost/mg** Dosage/(mg/m2)† Days of treatment/cycle Cost per cycle
AZA REGIMEN
Azacitidine €3.40/mg 75 7 €3,028.14
LDC REGIMEN
Cytarabine €0.0271/mg 150 7 €48.38
SDC REGIMEN*
Cytarabine/Idarubicin €965.16
Cytarabine €0.0271/mg 1000 7 €322.56
Idarubicin €10.52/mg 12 3 €642.60
Cytarabine/Mitoxantrone €543.55
Cytarabine €0.0271/mg 1000 7 €322.56
Mitoxantrone €3.62/mg 12 3 €220.99
Cytarabine/Daunorubicin €377.12
Cytarabine €0.0271/mg 1000 7 €322.56
Daunorubicin €0.179/mg 60 3 €54.56
Cytarabine/Idarubicin/Etoposide €848.68
Cytarabine €0.0271/mg 1000 4 €184.32
Idarubicin €10.52/mg 12 3 €642.60
Etoposide €0.043/mg 100 3 €21.76
Abbreviations: AZA = azacitidine; LDC = low dose chemotherapy; SDC = standard dose chemotherapy.
* Data were pooled corresponding to Spanish usual care weight for each treatment (pooled cost: €790. 41). ** All costs are expressed in ex-factory price and are
discounted according to RD 15/2010 † Mean body surface was assumed to be 1.7 m2.
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and to the lack of consensus in Spain, a threshold of
€50,000 per QALY gained, for end-of-life drugs, was
used according to the UK National Institute for Health
and Clinical Excellence [18,19].
The analysis was conducted taking into account the
typology of the patients and therefore treatment assigna-
tion to homogenous groups of patients was made ac-
cording this typology. In the AZA-001 trial, azacitidine
was administered to 110 patients, BSC to 79, LDC to 38
and SDC to 20 [9]. Our study replicated this treatment
pattern: BSC with blood product transfusions and antibi-
otics with granulocyte colony-stimulating factor for neu-
tropenic infection; LDC with cytarabine, 150 mg/m2 per
day subcutaneously for 7 days, every 28 days for at least
4 cycles; and SDC with cytarabine 1000 mg/m2 per day
for 7 days, plus 3 days of either intravenous daunorubi-
cin [60 mg/m2 per day], idarubicin [12 mg/m2 per day]
or mitoxantrone [12 mg/m2 per day]) or 3 days of idaru-
bicin [12 mg/m2 per day] and etoposide [100 mg/m2 per
day]. For a more exact approximation to the Spanish
context, the expert group suggested only including one
session of SDC treatment in the analysis, despite the fact
that in the AZA-001 trial patients received a median of
one session.
A global cost-effectiveness analysis of azacitidine vs.
BSC, LDC and SDC and a sub-analysis of azacitidinecompared with BSC and azacitidine compared with LDC
were made. The results of an analysis for azacitidine
compared only with SDC were considered not applicable
due to the low number of patients enrolled (low power
for small size samples).
Probabilistic sensitivity analysis was performed to
examine the combined effect of the uncertainty in all the
variable parameters (survival, treatment cessation, unit
cost, use of resources, etc.). Values were sampled from
the uncertainty distributions associated with each param-
eter. Where there were no estimates of parameter uncer-
tainty, ±30% intervals were assumed. To achieve this,
results were generated for a hypothetical sample of 50,000
individuals using a parametric Monte-Carlo simulation
based on the variability in the curve fit and extrapolation
in the efficacy and on the range of costs (maximum and
minimum) of the resources used. The log-normal distribu-
tion was used for survival data, a Weibull distribution for
treatment cessation, a beta distribution for utilities and AE
and a normal distribution for dosing and resource use
[20,21]. Uncertainty in the survival and treatment cessa-
tion variables was analyzed by incorporating the covari-
ance generated in the survival models [20,21].
Results
A cost-effectiveness analysis was performed to analyse
azacitidine vs. the three CCR options assessed in the
Table 3 Treatment costs per cycle
Azacitidine BSC LDC SDC
MDS treatment on treatment €4,911.24 €1,426.21 €2,671.20 €20,853.08
Pre-medication €0.70 €0 €2.11 €0
Treatment administration €442.40 €0 €380.20 16,344.02
Pharmacology €3,028.14 €0 €48.38 €790.41
Follow-up appointments €238.55 €238.55 €238.55 €0*
Blood/Platelet transfusion €926.07 €1,070.31 €1,754.35 €2,557.71
Concurrent Medication on treatment €37.90 €54.72 €65.86 €87.21
Routine tests on treatment €237.49 €62.63 €181.74 €1.073.74
MDS treatment off treatment €1,627.78 €1,772.02 €2,456.06 €3,259.42
Follow-up appointments €238.55 €238.55 €238.55 €238.55
Blood/Platelet transfusion €926.07 €1,070.31 €1,754.35 €2,557.71
Concurrent Medication off treatment €54.72 €54.72 €54.72 €54.72
Routine tests off treatment €62.63 €62.63 €62.63 €62.63
Annualized Adverse Events BSC €345.81 €345.81 €345.81 €345.81
Treatment administration BSC €0 €0 €0 €0
AML treatment €1,851.86 €1,851.86 €1,851.86 €1,851.86
Follow-up appointments €233.33 €233.33 €233.33 €233.33
Adverse events €345.81 €345.81 €345.81 €345.81
Concurrent Medication €132.18 €132.18 €132.18 €132.18
Blood/Platelet transfusion €1,070.31 €1,070.31 €1,070.31 €1,070.31
Routine tests €70.24 €70.24 €70.24 €70.24
Abbreviations: MDS = myelodysplastic syndrome; AML = acute myeloid leukaemia; BSC = best supportive care; LDC = low dose chemotherapy; SDC = standard
dose chemotherapy.
* Include only 1 chemotherapy session.
Crespo et al. Health Economics Review Page 5 of 102013, 3:28
http://www.healtheconomicsreview.com/content/3/1/28AZA-001 clinical trial (BSC, LDC and SDC). The ana-
lysis for the lifetime perspective of azacitidine vs. the
weighted mean survival of the CCR options showed 2.26
LY gained and 1.89 QALY gained. The survival gained
with azacitidine resulted in longer treatment time and
thus greater accumulated costs over a life-time horizon,
resulting in higher costs vs. the CCR options (€65,436)
(Table 4). Furthermore, the ICER value was €28,891/LY
gained and €34,673/QALY gained and was located under
the €50,000/QALY cost-effectiveness threshold (Figure 2).
Moreover, a sub-analysis of azacitidine compared with
BSC and LDC was also performed in order to show the dif-
ferences between the subgroups included in the analysis.Azacitidine vs. BSC
Azacitidine showed greater clinical benefit over a life-
time horizon compared with BSC. While azacitidine
added 4.05 years, BSC added only 1.88 years. Moreover,
azacitidine improved the quality of life, with 3.06 QALY
gained compared with 1.24 QALY gained using BSC.
Better overall survival with azacitidine resulted in lon-
ger treatment time and partially explained the greater
accumulated costs over a life-time horizon (Figure 3).The contribution of the MDS off-treatment cost in life-
time treatment burden was noteworthy.
One cycle of azacitidine cost €4,911 compared with €1,772
for BSC, although the difference was partially compensated
for by lower AE costs (€330 vs. €345). From the life-time per-
spective, the total cost of azacitidine was €72,112 higher than
the cost of BSC, mainly due to the higher pharmacological
cost of azacitidine. However, the reduction in the number of
transfusions, representing 32% and 45% of the entire treat-
ment cost of azacitidine and BSC, respectively, partly com-
pensated for the acquisition cost of the drug (Figure 4).
In terms of cost-effectiveness over a life-time horizon,
the incremental cost of azacitidine treatment was €33,111/
LY gained. When quality of life was taken into account,
the ICER was €39,610/QALY gained. Therefore, azacitidine
was considered a cost-effective option in the Spanish set-
ting due to the fact that the ICER value was situated under
the €50,000/QALY cost-effectiveness threshold (Figure 5).
Azacitidine vs. LDC
The same trend was observed in the comparison with LDC.
Azacitidine resulted in 2.39 more LY gained and 2.02 more
QALY gained compared with LDC. A cycle of treatment
with azacitidine cost €4,911 compared with €2,671 for LDC
Table 4 Cost-effectiveness analysis results over a life-time horizon
Indicator Costs LYs QALYs
Treatment AZA comparator AZA comparator AZA comparator
AZA vs. BSC €107,168 €35,090 4.05 1.88 3.06 1.24
ICER €33,111/LY gained € 39,610/QALY gained
AZA vs. LDC €115,537 €53,184 4.45 2.06 3.39 1.36
ICER €25,953/LY gained €30,531/QALY gained
AZA vs. SDC €106,422 €59,725 3.96 1.49 2.94 0.98
ICER €18,884/LY gained €23,804/QALY gained
AZA vs. CCR* €108,605 €43,170 4.11 1.85 3.11 1.22
ICER €28,891/LY gained €34,673/QALY gained
Abbreviations: AZA = Azacitidine; BSC = best supportive care; LDC = low dose chemotherapy; SDC = standard dose chemotherapy; CCR = conventional care
regimen; QALY = Quality adjusted life year; LY = Life year.
* Data were pooled corresponding to the number of patients in the AZA-001 study for each treatment.
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vs. €627). From the life-time perspective, the total cost of
azacitidine was €61,929 higher than LDC. As with BSC, the
main cost driver of the LDC arm was transfusions (Figure 4).
In terms of cost-effectiveness over a life-time horizon,
the incremental cost of azacitidine treatment was €25,953/
LY gained and €30,531/QALY gained, values located below
€50,000/QALY cost-effectiveness threshold (Figure 2).Azacitidine vs. SDC
Due to the low number of patients included in the SDC
treatment arm in the AZA-001 trial, this data was used only
in the overall analysis of the CCR options. The SDC treat-
ment cost/cycle was almost four times more expensive than
azacitidine. The main cost driver of SDC treatment was the
administration cost, due to hospitalization in patients re-
ceiving this treatment (28 days). There were also signifi-
cantly greater AE costs compared with azacitidine.Figure 2 Cost-effectiveness plane AZA vs. BSC and AZA vs. LDC and A
LDC = low dose chemotherapy; SDC = standard dose chemotherapy; CCR
LY = life year; GDP = Gross domestic product.Sensitivity Analysis
The sensitivity analysis showed that azacitidine was a cost-
effective option in 96.49% of the simulated cases €50,000/
QALY willingness-to-pay. In the subgroup analysis, the com-
parison shows that the probability of azacitidine being cost-
effective below the €50,000/QALY threshold was 83.21% vs.
BSC and 91.21% vs. LDC (Figure 5). The probabilistic sensitivity
analysis confirmed the robustness of the results of the model.
Discussion
The crude incidence rate of MDS in Spain is 8.1/100,000
[22]. According to the European Medicines Agency
(EMA) MDS is considered an orphan disease [23]. Life-
threatening diseases with a prevalence rate lower than
5/10,000 are considered rare diseases [24]. Azacitidine was
granted orphan drug status in the EU for the treatment of
MDS in February 2002 and for the treatment of AML
with 20-30% blasts in the marrow in November 2007.
Orphan drugs frequently present ICER values far aboveZA vs. CCR. AZA = azacitidine; BSC = best supportive care;





















Azacitidine BSC Azacitidine LDC
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Figure 3 Cost of treatments and overall survival (treatment cycles). MDS = myelodysplastic syndrome; AML = acute myeloid leukaemia;
AZA = Azacitidine; BSC = best supportive care; LDC = low dose chemotherapy.
Crespo et al. Health Economics Review Page 7 of 102013, 3:28
http://www.healtheconomicsreview.com/content/3/1/28established cost-effectiveness thresholds, but this is not
the case with azacitidine, which has a low ICER value
compared with other orphan drugs [23-28]. At present,
there is no accepted cost-effectiveness threshold for
this type of extreme clinical situation. Nevertheless,
even if the choice of the €50,000/QALY thresholdFigure 4 Cost structure (%) of each treatment arm. AML = acute myeloidmight be questioned, it is within the range used in similar
studies [19,25-30]. Furthermore, according to the recom-
mendations of the Commission on Macroeconomics and
Health Gross Domestic Product (GDP)-based threshold
of the World Health Organisation, the maximum thres-
hold would be €68,457/QALY (3xGDP/per capita) [31].leukaemia; BSC = best supportive care; LDC = low dose chemotherapy.
Figure 5 Cost-effectiveness acceptability curves: Azacitidine vs. BSC and Azacitidine vs. LDC. AZA = azacitidine; BSC = best supportive care;
LDC = low dose chemotherapy; CCR = conventional care regimen.
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investigation and development of this type of drug. Ac-
cording to the Spanish Ministry of Health, Social Ser-
vices and Equality, orphan drugs are “medicines that for
economic reasons are unlikely to be investigated and
supported by pharmaceutical companies”. Furthermore,
in recent years, 87% of orphan drugs positively evaluated
by the EMA were licensed in Spain. Most were for use
in oncology or endocrinology and metabolism-related
diseases [32].
Several studies have assessed the clinical benefits of
azacitidine compared with CCR and have shown clinical
superiority, but economic evaluations are lacking. A
Canadian study comparing azacitidine with CCR options
(BSC, LDC, SDC) confirmed the superiority of azacitidine
in terms of cost-effectiveness, with a global ICER of CAD
84,395/QALY gained, which was below the 3xGDP WHO
threshold (38,710 × 3) [19] for Canada. The study also
showed the superiority of azacitidine compared with each
of the other treatment options, with the following ICER
values: CAD 84,395/QALY gained for BSC, CAD 88,786/
QALY gained for LDC and CAD 28,501/QALY gained for
SDC [33]. Though not included in our analysis due to the
small number of patients participating in the AZA-001
study, the results of SDC treatment in Spain confirmed
the trend shown in the Canadian study of an ICER
ratio lower than those of the other CCR options.
A recent study compared azacitidine with decitabine
and found that azacitidine was a cost-effective treatment
for MDS according to U.S. National Healthcare Input
data [34], with a comparative gain of 0.171 more QALYs
and savings of €15,890 over a 2-year period. However,
the relevance of the study is limited, mainly becausesurvival data was retrieved from two different phase III
trials and no direct comparison was made.
This study nevertheless has some limitations. It is rec-
ommended to consider the fact that this approach is
based on a mathematical model which depends mainly
on the accuracy of available data in the moment of the
analysis and should be treated as it.
To obtain a global cost-effectiveness analysis, a weighted
average of individual cost-effectiveness ratios was used. In
the absence of local patient treatment distribution data,
the ICERs were weighted according to the distribution of
patients for each treatment arm in the AZA-001 trial.
In the AZA-001 study, no significant difference be-
tween azacitidine and SDC was found [9], and thus the
cost-effectiveness analysis for this group might also not
be significant.
The cost and resource data used in the model were the
best available and came from published data in Spain, ob-
tained from clinical trials, local databases and relevant lit-
erature. However, the data sources for efficiency had
limitations derived from the limitations, structure and
temporality of the trials. In the absence of end-of-life sur-
vival data from the AZA-001 study, survival curves were
extrapolated using the log-normal distribution. Consider-
ing that major clinical benefits are visible in the long term
and that our results are difficult to collate due to the fact
that MDS is an orphan disease, the clinical experts agreed
on the reasonableness of our findings.
However, there is uncertainty about the information
on the quality of life as mapping using regression was
used to obtain EQ-5D utility scores from the QLQ-C30
and SF-12 scores. Another limitation of utility scores is
that QLQ-C30 scores do not include information on
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carry out the activities of daily living. Statistical analysis
was used to reduce limitations due to data variability by
means of sensitivity analysis, which is used to assess un-
certainty by assigning specific distribution probabilities
to all data included in the model in order to simulate al-
ternative values. For further analysis, improvements in
the quality of life due to the independence of blood
transfusion may be included. Likewise, azacitidine may
be indicated in cases where blood transfusion is rejected
for religious reasons.
Though economic analysis is an important factor in
decision making, the clinical perspective remains crucial,
and from this perspective, although it is a serious, life-
threatening disease, MDS has a high unmet diagnosis
and treatment need.
First, due to differences in diagnostic methods and classi-
fication, current prevalence rates around Europe are lack-
ing [35]. Secondly, at present, the lack of standardization of
MDS in Europe leads to difficulties in determining the ap-
propriate treatment. Thirdly, CCR options are often associ-
ated with significant toxicity and morbidity. Azacitidine, on
the other hand, showed clinical superiority in terms of out-
comes and improvements in safety compared with conven-
tional treatment alternatives [9].Conclusions
There is an urgent need for better and safer treatment
options for MDS. Azacitidine showed clinical superiority
to all of the treatment alternatives considered and the
cost-effectiveness analysis showed that azacitidine is a
cost-effective treatment option in the Spanish context.
End-of-life economic analysis assigned a higher cost to
azacitidine treatment partly due to the greater best sup-
portive care costs associated with longer survival.
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